Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLARITHROMYCIN (clarithromycin) by Molecular Devices is 12. Approved for mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, streptococcus pneumoniae [see ] and 14 more indications. First approved in 2005.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Clarithromycin is a macrolide antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%. For a single 500 mg dose of clarithromycin, food slightly delays the onset of clarithromycin…
Worked on CLARITHROMYCIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo